{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:51:47Z","timestamp":1792212707979,"version":"4.4.0"},"reference-count":9,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.5582\/ddt.2025.01111","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:06:01Z","timestamp":1763589961000},"page":"435-436","source":"Crossref","is-referenced-by-count":6,"title":["Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval"],"prefix":"10.5582","volume":"19","author":[{"given":"Chenru","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao Medical College, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Gonzalez IL. Barth syndrome: TAZ gene mutations, mRNAs, and evolution. Am J Med Genet A. 2005; 134:409-414.","DOI":"10.1002\/ajmg.a.30661"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Miller PC, Ren M, Schlame M, Toth MJ, Phoon CKL. A Bayesian analysis to determine the prevalence of Barth syndrome in the pediatric population. J Pediatr. 2020; 217:139-144.","DOI":"10.1016\/j.jpeds.2019.09.074"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jefferies JL. Barth syndrome. Am J Med Genet C Semin Med Genet. 2013; 163C:198-205.","DOI":"10.1002\/ajmg.c.31372"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Clarke SL, Bowron A, Gonzalez IL, <i>et al<\/i>. Barth syndrome. Orphanet J Rare Dis. 2013; 8:23.","DOI":"10.1186\/1750-1172-8-23"},{"key":"5","unstructured":"5. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. <i>https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-first-treatment-barth-syndrome<\/i> (Accessed October 5, 2025)."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, Santulli G. Elamipretide: A review of its structure, mechanism of action, and therapeutic potential. Int J Mol Sci. 2025; 26:944.","DOI":"10.3390\/ijms26030944"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Reid Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ. A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021; 23:471-478.","DOI":"10.1038\/s41436-020-01006-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024; 26:101138.","DOI":"10.1016\/j.gim.2024.101138"},{"key":"9","unstructured":"9. FORZINITY (elamipretide) injection, for subcutaneous use. <i>https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215244s000lbl.pdf<\/i> (accessed October 5, 2025)."}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01111\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:19:59Z","timestamp":1768018799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01111\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":9,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01111","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"2025.01111"}}